National Advisory Council for Environmental Policy and Technology (NACEPT)
Endocrine Disruptor Methods Validation Subcommittee (EDMVS)
First Plenary Meeting
October 30-31, 2001

Washington Dulles Airport Hilton
Grand Ballroom III
13869 Park Center Road
Herndon, VA 20171
703-478-2900

DRAFT Agenda

Meeting Objectives:

- Present overview of the Environmental Protection Agency's (EPA) Endocrine Disruptor Program.
- Provide background information on test protocol validation and approaches.
- Develop clear understanding of the EDMVS scope, purpose, and operating procedures.
- Determine next steps.

Tuesday, October 30, 2001

9:00 – 9:15 Welcome and Opening Comments
Dr. Vanessa Vu, Chair, Director, Office of Science Coordination and Policy, (OSCP), EPA
Dr. William Benson, Vice-Chair, Director, Gulf Ecology Division, National Health and Environmental Effects Research Laboratory, Office of Research and Development, (ORD), EPA

9:15 – 9:45 Introductions and Agenda Review
Paul De Morgan, Facilitator, RESOLVE

9:45 – 10:00 Orientation to the Federal Advisory Committee Act and Ethics
Peter Redmond, NACEPT Designated Federal Official (DFO), Office of Cooperative Environmental Management, (OCEM), EPA

10:00 – 10:15 Overview of NACEPT
Peter Redmond, NACEPT DFO, OCEM, EPA

10:15 – 10:30 Break

10:30 – 11:15 Overview of EPA's Regulatory Program for Endocrine Disruptors
Gary Timm, OSCP, EPA

11:15 – 12:00 Overview of EPA's Research Program for Endocrine Disruptors
Dr. Elaine Francis, ORD, EPA

12:00 – 1:00 Lunch

1:00 – 1:30 Overview of the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) Test Protocol Validation Process
Dr. Dave Hattan, Director, Division of Health, Food and Drug Administration

1:30 – 2:15 Endocrine Disruptor Screening Program's (EDSP) Approaches to Test Protocol Validation and Process: Relationships Between ICCVAM, Organization for Economic Co-operation and Development (OECD), EPA, and EDMVS
Gary Timm, OSCP, EPA

2:15 – 3:00 EDSP's Test Protocol Validation Program: Status and Timeline
Jim Kariya, OSCP, EPA

3:00 – 3:15 Break

3:15 – 4:30 Illustration of OECD Test Protocol Validation Process: the Uterotrophic Assay
Dr. James W. Owens, Procter and Gamble

4:30 – 5:15 Public Comment
Members of the public will be given an opportunity to comment on any aspect of the EDMVS work. The amount of time given to each individual will depend on the number of people wishing to provide comment.

5:15 – 5:30 Setting the Stage for Day Two

<u>Wednesday, October 31, 2001</u>

9:00 – 9:45 Overview of the Mission Statement
Jane Smith, EDMVS DFO, OSCP, EPA

9:45 – 10:45 EDMVS Operating Procedures
Paul De Morgan, Facilitator, RESOLVE

10:45 – 11:00 Break

11:00 – 12:15 Looking Forward and Planning Next Steps

- Discuss status and timeline.
- Identify information needs.
- Discuss agenda items and dates for next meeting(s).
- Review action items.

12:15 – 12:30 Summary of Meeting and Closing Comments

12:30 Adjourn